Common Stock and Common Stock Purchase Warrants (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands						1 Months Ended	3 Months Ended	9 Months Ended
	Mar. 07, 2024	Feb. 15, 2024	Jan. 15, 2024	Dec. 07, 2023	Nov. 28, 2023	Feb. 28, 2023	Sep. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split					1-for-15
Common stock, shares authorized							50,000,000	50,000,000		50,000,000
Stock Issused and outstanding description				every 15 shares of the Company’s common stock that were issued and outstanding were automatically combined into one issued and outstanding share, without any change in par value of such shares.
Debt instrument fee description	On March 7, 2024, the Company received a notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that, for the prior 30 consecutive business days (through March 6, 2024), the market value of the Company’s listed securities had been below the minimum of $35 million required for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). The Company was provided 180 calendar days, or until September 3, 2024, to regain compliance with the rule. The Company did not regain compliance with the rule during the allotted time period. Accordingly, on September 10, 2024, the Company received a staff determination letter from the Nasdaq Listing Qualifications Department, stating that unless the Company timely requested a hearing before a Nasdaq Hearings Panel (the “Panel”) to appeal the staff determination, the Company’s securities would be subject to suspension and delisting. The Company timely requested a hearing before the Panel, which was held on October 29, 2024.
At-the-market equity facility, shares								627,302
At-the-market equity facility, value								$ 977
Payments for commissions percentage								3.00%
Issued for services							$ 150	$ 601	$ 747
Warrant price decrease		$ 0.52
Share price		0.37709668
Exercise price		$ 23.48
Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price							$ 23.48	$ 23.48		$ 23.48
Class of Warrant or Right, Outstanding							11,937,450	11,937,450		11,937,450
Purchase of warrants							795,830	795,830		795,830
Exercise price, post reverse-split							$ 24.00	$ 24.00		$ 24.00
Lucid Diagnostics Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, dividends shares		3,331,747	38
Vendors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued								200,809
Issued for services								$ 200
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued							171,052	200,809	100,000
Issued for services
Common Stock [Member] | Lucid Diagnostics Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, dividends shares			100
April 2022 Senior Convertible Note and September 2022 Senior Convertible Note [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible common stock shares issued upon conversion							574,424	574,424
Debt Instrument, Convertible, If-converted Value in Excess of Principal								$ 980
Employee Stock Purchase Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock issued								34,332
Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split						1-for-5
Common stock, shares authorized						50,000,000
Minimum [Member] | Series Z Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price, post reverse-split							$ 0.52	$ 0.52		$ 0.52
Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reverse stock split						1-for-15
Common stock, shares authorized						250,000,000